Comparisons of analytical sensitivity of the nine primer sets with TaqMan-based and SYBR Green-based RT-qPCR using SARS-CoV-2 positive nasopharyngeal swabs from 3 patients including one infected by B.1.351 lineage (all samples were separately diluted for 3 times into 4 series of tenfold dilutions. All were measured in replicates. ND: not detected.

We have developed two TaqMan real-time reverse transcription-PCR assays to detect SARS-CoV-2. The designed primers target the nucleocapsid (N) and open reading frame (ORF) 1b gene regions, where the probes discriminate SARS-CoV-2 from other human and animal CoVs.

The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world. Labs 

Convenient —use your current real-time PCR instrumentation to conduct research testing of SARS-CoV-2 samples. Scalable—run a few or hundreds of samples to identify one or many mutations. Unique, streamlined workflow —combines our gold-standard TaqMan SNP Genotyping Assays with a 1-step RT-PCR reaction; go from RNA to results in just over

The TaqMan SARS-CoV-2 Mutation Panel is a convenient, scalable reflex solution to identify the presence of relevant COVID-19 mutations using a customizable menu of verified real-time PCR

Conclusion: Our study indicates that TaqMan SARS-CoV-2 mutation panel molecular genotyping assays detect and differentiate all published 

The TaqMan SARS-CoV-2, Flu A/B, RSV RNA Control contains targets specific to the SARS-CoV-2, influenza A/B, and RSV genomic regions targeted by the TaqMan SARS-CoV-2, FluA/B RSV RT-PCR Assay Kit. It is recommended for use with this assay as a positive control to ensure reaction setup and reagent integrity when interpreting test results.

Applied Biosystems™ TaqMan™ SARS-CoV-2 Mutation Assays, S.P681R. TQMN SARSCOV MUTASSY,S.P681R, Quick Order Only. Manufacturer: Applied Biosystems™ A51822. Catalog No. A51822. $1,034.00 / Each of 1. Due to product restrictions, please Sign In to purchase or view availability for this product. Provide Content Correction.

over a 6-week period during the months of april and may , we set out to assess the thermofisher taqman mutation panel genotyping assay, initially for three mutations of concern and then for an additional two mutations of concern, against sars-cov-2-positive clinical samples and the corresponding covid-19 genomics uk consortium (cog-uk)

Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages; however, there can be limitations due to sequence dropout 

Development of two TaqMan real-time reverse transcription-PCR assays for the detection of severe acute respiratory syndrome coronavirus-2 The outbreak of coronavirus disease (COVID-19) in Wuhan, China, was caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).